by Willow Tohi, Natural News:
-
- Why: To explore alternative cancer treatments like ivermectin, which is cheap and lacks a profit-driven research model.
-
- Who: Governor Ron DeSantis and First Lady Casey DeSantis, with backing from Surgeon General Dr. Joseph Ladapo.
-
- When: Announced on World Cancer Research Day, September 24, 2025.
- Where: University of South Florida.
TRUTH LIVES on at https://sgtreport.tv/
-
- What: Florida is investing $60 million into the Florida Cancer Innovation Fund, focusing on repurposed drugs and preventative nutrition.
On World Cancer Research Day, September 24, Florida’s Governor Ron DeSantis and First Lady Casey DeSantis announced a significant investment of $60 million into cutting-edge cancer research. The funds, part of the Florida Cancer Innovation Fund, aim to explore alternative cancer treatments using repurposed drugs, with a particular focus on ivermectin, a well-established anti-parasitic medication. This initiative reflects the state’s commitment to finding innovative solutions that can benefit taxpayers and patients alike, despite the lack of financial incentives for pharmaceutical companies.
The role of ivermectin in cancer research
Ivermectin, an anti-parasitic medication widely used to treat parasitic infections, has drawn attention for its potential applications in cancer treatment. This interest stems from promising pre-clinical data suggesting its ability to inhibit cancer cell proliferation. Dr. Joseph Ladapo, Florida’s surgeon general, emphasized the importance of investigating alternative therapies that can provide affordable and accessible treatment options. “We’re uniquely positioned to do this because big pharma doesn’t profit from relatively cheap drugs like ivermectin,” he stated. First Lady Casey DeSantis, a cancer survivor herself, echoed this sentiment, underscoring the need to look beyond conventional treatments.
Repurposing ivermectin for cancer treatment
While ivermectin is not currently approved by the FDA for cancer treatment, there is a growing body of research supporting its potential. Dr. Paul Marik, a prominent researcher in the field, highlighted its effectiveness in combination with other drugs. “Ivermectin inhibits cancer cell viability, showing promise in treating several types of cancer,” he told a press conference. However, cautious optimism is warranted given the limitations in clinical evidence. Some experts caution against the use of ivermectin due to insufficient rigorous evidence, emphasizing that further research is essential to validate its clinical effectiveness.
Historical context and current challenges
The push to repurpose ivermectin for cancer treatment is not without historical context. The off-patent nature of ivermectin—meaning it is inexpensive—has long been a barrier to pharmaceutical investment in expanding its use. This phenomenon exemplifies the broader debate surrounding drug repurposing and the emphasis on affordable treatments. Despite the potential benefits, these drugs often lack the financial incentives that drive large-scale clinical trials, thus remaining underutilized.
